COPT Defense Properties (NYSE:CDP) Announces Quarterly Dividend of $0.32

COPT Defense Properties (NYSE:CDP) announced a quarterly dividend on Thursday, May 14th. Stockholders of record on Tuesday, June 30th will be paid a dividend of 0.32 per share on Wednesday, July 15th. This represents a c) annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend is Tuesday, June 30th.

COPT Defense Properties has increased its dividend payment by an average of 0.0%per year over the last three years.

COPT Defense Properties Stock Down 0.2%

Shares of NYSE CDP opened at $31.64 on Friday. The firm’s 50-day moving average price is $31.73 and its 200-day moving average price is $30.53. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 1.63. The stock has a market capitalization of $3.59 billion, a price-to-earnings ratio of 22.93 and a beta of 0.80. COPT Defense Properties has a 12-month low of $26.44 and a 12-month high of $33.29.

COPT Defense Properties (NYSE:CDP) last announced its earnings results on Monday, April 27th. The company reported $0.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.68 by ($0.34). The business had revenue of $200.64 million for the quarter, compared to analysts’ expectations of $185.10 million. COPT Defense Properties had a net margin of 20.10% and a return on equity of 10.02%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.65 earnings per share. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. On average, equities research analysts anticipate that COPT Defense Properties will post 2.78 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Philip L. Hawkins sold 5,536 shares of COPT Defense Properties stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $32.71, for a total transaction of $181,082.56. Following the completion of the sale, the director owned 15,188 shares in the company, valued at $496,799.48. This trade represents a 26.71% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.66% of the stock is owned by insiders.

Institutional Investors Weigh In On COPT Defense Properties

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDP. Norges Bank bought a new stake in COPT Defense Properties during the 4th quarter valued at about $39,685,000. Alliancebernstein L.P. lifted its holdings in COPT Defense Properties by 16.8% during the 3rd quarter. Alliancebernstein L.P. now owns 8,457,373 shares of the company’s stock valued at $245,771,000 after buying an additional 1,215,936 shares in the last quarter. GRS Advisors LLC bought a new stake in COPT Defense Properties during the 3rd quarter valued at about $28,399,000. Two Sigma Investments LP lifted its holdings in COPT Defense Properties by 289.9% during the 3rd quarter. Two Sigma Investments LP now owns 900,047 shares of the company’s stock valued at $26,155,000 after buying an additional 669,181 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its holdings in COPT Defense Properties by 51.8% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,896,161 shares of the company’s stock valued at $52,713,000 after buying an additional 647,449 shares in the last quarter.

About COPT Defense Properties

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.